The ripple effect of the anacetrapib/CETP inhibitor story.......Amgen kills off its AMG 899 (formerly TA-8995) CETP inhibitor program that it bought from Dezima back in 2015 for $300 million upfront ($1.25 billion in additional potential milestones).

Fierce Biotech: Amgen kills off CETP inhibitor after seeing Merck data

Endpoints News: Amgen buries the last big CETP drug, marking the bitter end of a blockbuster quest

This leaves one last viable CETP inhibitor program left standing. DalCor is pursuing previously failed dalcetrapib in a Phase 3 trial focusing on subjects with a particular genotype in the ADCY9 gene, a pharmacogenetic interaction identified in pharmacogenetic analysis of the dal-outcomes study.